JO3383B1 - مثبطات cdc7 - Google Patents

مثبطات cdc7

Info

Publication number
JO3383B1
JO3383B1 JOP/2014/0067A JOP20140067A JO3383B1 JO 3383 B1 JO3383 B1 JO 3383B1 JO P20140067 A JOP20140067 A JO P20140067A JO 3383 B1 JO3383 B1 JO 3383B1
Authority
JO
Jordan
Prior art keywords
cdc7 inhibitors
cdc7
inhibitors
useful
pharmaceutically acceptable
Prior art date
Application number
JOP/2014/0067A
Other languages
English (en)
Inventor
Andrew Woods Timothy
Dean Dally Robert
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3383B1 publication Critical patent/JO3383B1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير مركبات أيزوإندولينون، أو ملح مقبول صيدليًا منها، والتي تثبِّط CDC7، وبالتالي يمكن أن تكون مفيدة في علاج السرطان.
JOP/2014/0067A 2013-03-14 2014-03-04 مثبطات cdc7 JO3383B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361782798P 2013-03-14 2013-03-14
US201361789108P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
JO3383B1 true JO3383B1 (ar) 2019-03-13

Family

ID=50382704

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0067A JO3383B1 (ar) 2013-03-14 2014-03-04 مثبطات cdc7

Country Status (36)

Country Link
US (1) US9156824B2 (ar)
EP (1) EP2970221B1 (ar)
JP (1) JP6064079B2 (ar)
KR (1) KR101718645B1 (ar)
CN (1) CN105008351B (ar)
AP (1) AP2015008734A0 (ar)
AU (1) AU2014228374B2 (ar)
BR (1) BR112015020466B1 (ar)
CA (1) CA2900773C (ar)
CL (1) CL2015002530A1 (ar)
CR (1) CR20150416A (ar)
CY (1) CY1119199T1 (ar)
DK (1) DK2970221T3 (ar)
EA (1) EA027012B1 (ar)
ES (1) ES2639793T3 (ar)
GT (1) GT201500263A (ar)
HR (1) HRP20171151T1 (ar)
HU (1) HUE033482T2 (ar)
IL (1) IL240962B (ar)
JO (1) JO3383B1 (ar)
LT (1) LT2970221T (ar)
ME (1) ME02805B (ar)
MX (1) MX363438B (ar)
MY (1) MY188145A (ar)
NZ (1) NZ710392A (ar)
PE (1) PE20151654A1 (ar)
PH (1) PH12015502091B1 (ar)
PL (1) PL2970221T3 (ar)
PT (1) PT2970221T (ar)
RS (1) RS56122B1 (ar)
SG (1) SG11201507541PA (ar)
SI (1) SI2970221T1 (ar)
TN (1) TN2015000349A1 (ar)
TW (1) TWI622396B (ar)
UA (1) UA116125C2 (ar)
WO (1) WO2014143601A1 (ar)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2906555T1 (sl) * 2012-10-15 2017-02-28 Pfizer Ireland Pharmaceuticals Operations Support Group Postopek za pripravo vorikonazola in njegovih analogov
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
ME03780B (me) 2013-01-15 2021-04-20 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
ES2689526T3 (es) 2013-03-14 2018-11-14 Janssen Pharmaceutica Nv Moduladores de P2X7
JO3773B1 (ar) 2013-03-14 2021-01-31 Janssen Pharmaceutica Nv معدلات p2x7
AU2014230814B2 (en) 2013-03-14 2017-12-21 Boehringer Ingelheim International Gmbh Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C
TWI627174B (zh) 2013-03-14 2018-06-21 比利時商健生藥品公司 P2x7調控劑
EP3112366B1 (en) 2013-03-14 2018-02-28 Janssen Pharmaceutica NV P2x7 modulators
EA201690458A1 (ru) 2013-08-23 2016-07-29 Инсайт Корпорейшн Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
KR102510588B1 (ko) 2014-09-12 2023-03-17 베링거 인겔하임 인터내셔날 게엠베하 카텝신 c의 스피로사이클릭 억제제
EA201790600A1 (ru) 2014-09-12 2017-07-31 Янссен Фармацевтика Нв Модулирующие p2x7 n-ацил-триазолопиразины
WO2016039977A1 (en) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulators
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
ES2845048T3 (es) * 2016-09-22 2021-07-23 Cancer Research Tech Ltd Preparación y usos de derivados de pirimidinona
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
CN108383771A (zh) * 2018-01-08 2018-08-10 华东师范大学 手性3,3-二取代异吲哚啉-1-酮衍生物及其合成方法和应用
GB201807147D0 (en) 2018-05-01 2018-06-13 Oncologica Uk Ltd Therapeutic combination
NL2021185B1 (en) 2018-06-26 2020-01-06 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Combination Therapy and Use Thereof for Treating Cancer
MA53722A (fr) 2018-09-28 2022-03-30 Janssen Pharmaceutica Nv Modulateurs de la monoacylglycérol lipase
WO2020065613A1 (en) 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
WO2020212434A1 (en) * 2019-04-16 2020-10-22 Janssen Pharmaceutica Nv Fused isoindolin-1-one derivatives useful as grk2 inhibitors
CN114555596B (zh) 2019-09-30 2025-02-25 詹森药业有限公司 放射性标记的mgl pet配体
US11891387B2 (en) 2020-03-26 2024-02-06 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0400970D0 (sv) * 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
US7576082B2 (en) * 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
ATE545416T1 (de) * 2006-10-12 2012-03-15 Xenon Pharmaceuticals Inc Verwendung von spiro-oxindol-verbindungen als therapeutika
SG182187A1 (en) * 2007-06-08 2012-07-30 Abbott Gmbh & Co Kg 5-heteroaryl substituted indazoles as kinase inhibitors
US8648069B2 (en) * 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors

Also Published As

Publication number Publication date
HK1212696A1 (en) 2016-06-17
MY188145A (en) 2021-11-23
MX363438B (es) 2019-03-22
JP6064079B2 (ja) 2017-01-18
NZ710392A (en) 2020-05-29
TW201521726A (zh) 2015-06-16
CL2015002530A1 (es) 2016-03-28
KR20150119101A (ko) 2015-10-23
MX2015012583A (es) 2016-01-20
JP2016512498A (ja) 2016-04-28
BR112015020466A8 (pt) 2019-11-12
UA116125C2 (uk) 2018-02-12
RS56122B1 (sr) 2017-10-31
CN105008351B (zh) 2017-03-15
EA027012B1 (ru) 2017-06-30
PL2970221T3 (pl) 2017-11-30
CR20150416A (es) 2015-09-16
CN105008351A (zh) 2015-10-28
TWI622396B (zh) 2018-05-01
WO2014143601A1 (en) 2014-09-18
AU2014228374B2 (en) 2016-09-01
BR112015020466B1 (pt) 2022-07-26
TN2015000349A1 (en) 2017-01-03
PH12015502091A1 (en) 2016-01-18
CA2900773C (en) 2018-04-17
SI2970221T1 (sl) 2017-08-31
EP2970221A1 (en) 2016-01-20
GT201500263A (es) 2016-03-02
KR101718645B1 (ko) 2017-03-21
SG11201507541PA (en) 2015-10-29
IL240962A0 (en) 2015-11-30
US9156824B2 (en) 2015-10-13
ME02805B (me) 2018-01-20
DK2970221T3 (en) 2017-07-31
AP2015008734A0 (en) 2015-09-30
AU2014228374A1 (en) 2015-08-06
ES2639793T3 (es) 2017-10-30
CA2900773A1 (en) 2014-09-18
EA201591509A1 (ru) 2015-12-30
BR112015020466A2 (pt) 2017-07-18
HUE033482T2 (en) 2017-12-28
LT2970221T (lt) 2017-09-11
HRP20171151T1 (hr) 2017-10-06
IL240962B (en) 2020-04-30
EP2970221B1 (en) 2017-06-28
US20140275121A1 (en) 2014-09-18
CY1119199T1 (el) 2018-02-14
PH12015502091B1 (en) 2019-01-11
PE20151654A1 (es) 2015-11-12
PT2970221T (pt) 2017-09-22

Similar Documents

Publication Publication Date Title
PH12015502091A1 (en) Cdc7 inhibitors
PH12017500881B1 (en) Aurora a kinase inhibitor
IL256874B (en) Immune checkpoint suppressors for use in the treatment of blood-borne cancers
EP3247353A4 (en) Heterocyclic itk inhibitors for treating inflammation and cancer
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
IL268430A (en) Methods for treating cancer using hsp90 inhibitors
MX2015006478A (es) Inhibidores de glutaminasa y metodos de empleo.
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
WO2014165090A8 (en) Compounds for the treatment of tuberculosis
EP3664803A4 (en) DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS
EP3131552A4 (en) Methods for treating cancer using tor kinase inhibitor combination therapy
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
GB201702160D0 (en) Inhibitors for use in therapy
MX2015013021A (es) 5-bromo-indirrubinas.
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
NZ711523A (en) Use of sedoheptulose for prevention or treatment of inflammation
WO2014160628A3 (en) Articles and methods for preventing and treating dermatologic adverse events
EP3025711A4 (en) Medicine for preventing or treating hypertension
EP3674398A4 (en) ECHOVIRUS FOR TUMOR TREATMENT
EP3131550A4 (en) Methods for treating cancer using tor kinase inhibitor combination therapy
HK40031759A (en) Dhodh inhibitor for use in treating hematologic cancers
HK1261928A1 (en) Combination therapy for treating malignancies
HK1259979A1 (en) Combination therapy for treating malignancies